Hemispherx Enters Into an Agreement With myTomorrows for an Early Access Program for Rintatolimod in Europe
10 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Impatients, N.V., a...